Phillip Joseph

Dr. Phillip Joseph

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Chest
Verified
Journal Article
Closed access
PJPhillip Joseph
Phillip Joseph
CACarlo Arevalo
Carlo Arevalo
RORudolf K.F. Oliveira
Rudolf K.F. Oliveira
MFMariana Faria-Urbina
Mariana Faria-Urbina
DFDonna Felsenstein
Donna Felsenstein
DSDavid M. Systrom
David M. Systrom

5 June 2011
Verified
Conference Paper
Closed access
MGMathieu Gruber
Mathieu Gruber
PJPhillip Joseph
Phillip Joseph
TCTze Pei Chong
Tze Pei Chong

11 April 2023 in Chest
Verified
Journal Article
Closed access
PJPhillip Joseph
Phillip Joseph
ISInderjit Singh
Inderjit Singh
Rudolf OliveiraRudolf Oliveira
Rudolf Oliveira
CCChristine A. Capone
Christine A. Capone
MMMary P. Mullen
Mary P. Mullen
DSDavid M. Systrom
David M. Systrom

6 May 2022 in Chest
Verified
Journal Article
Closed access
PJPhillip Joseph
Phillip Joseph
RPRosa Pari
Rosa Pari
SMSarah Miller
Sarah Miller
AWArabella Warren
Arabella Warren
MSMary Catherine Stovall
Mary Catherine Stovall
DSDavid M. Systrom
David M. Systrom

1 May 2024 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
LMLindsay McAlpine
Lindsay McAlpine
AZAdeel S. Zubair
Adeel S. Zubair
PJPhillip Joseph
Phillip Joseph
SSSerena Spudich
Serena Spudich
ObjectivesTo report a case-control study of new-onset small fiber neuropathy (SFN) after COVID-19 with invasive cardiopulmonary exercise testing (iCPET). SFN is a critical objective finding in long COVID and amenable to treatment.MethodsA retrospective ...

1 January 2023 in Pulmonary Circulation
Verified
Journal Article
Open access
PJPhillip Joseph
Phillip Joseph
SSStella Savarimuthu
Stella Savarimuthu
JZJiayi Zhao
Jiayi Zhao
XYXiting Yan
Xiting Yan
HOHannah T. Oakland
Hannah T. Oakland
ISInderjit Singh
Inderjit Singh
Pulmonary hypertension (PH) in interstitial lung disease (ILD) is associated with increased mortality and impaired exertional capacity. Right heart catheterization is the diagnostic standard for PH but is invasive and not readily available. Noninvasive physiologic evaluation may predict PH in ILD. Forty‐four patients with PH and ILD (PH‐ILD) were compared with 22 with ILD alone (non‐PH ILD). Six‐min walk distance (6MWD, 223 ± 131 vs. 331 ± 125 m, p = 0.02) and diffusing capacity for carbon monoxide (DLCO, 33 ± 14% vs. 55 ± 21%, p < 0.001) were lower in patients with PH‐ILD. PH‐ILD patients exhibited a lower gas‐exchange derived pulmonary vascular capacitance (GXCAP, 251 ± 132 vs. 465 ± 282 mL × mmHg, p < 0.0001) and extrapolated maximum oxygen uptake (VO2max) (56 ± 32% vs. 84 ± 37%, p = 0.003). Multivariate analysis was performed to determine predictors of VO2max. GXCAP was the only variable that predicted extrapolated VO2max among PH‐ILD and non‐PH ILD patients. Receiver operating characteristic curve analysis assessed the ability of individual noninvasive variables to distinguish between PH‐ILD and non‐PH ILD patients. GXCAP (area under the curve [AUC] 0.85 ± 0.04, p < 0.0001) and delta ETCO2 (AUC 0.84 ± 0.04, p < 0.0001) were the strongest predictors of PH‐ILD. A CART analysis selected GXCAP, estimated right ventricular systolic pressure (eRVSP) by echocardiogram, and FVC/DLCO ratio as predictive variables for PH‐ILD. With this analysis, the AUC improved to 0.94 (sensitivity of 0.86 and sensitivity of 0.93). Patients with a GXCAP ≤ 416 mL × mmHg had an 82% probability of PH‐ILD. Patients with GXCAP ≤ 416 mL × mmHg and high FVC/DLCO ratio >1.7 had an 80% probability of PH‐ILD. Patients with GXCAP ≤ 416 mL × mmHg and an elevated eRVSP by echocardiogram >43 mmHg had 100% probability of PH‐ILD. The incorporation of GXCAP with either eRVSP or FVC/DLCO ratio distinguishes between PH‐ILD and non‐PH‐ILD with high probability and may therefore assist in determining the need to proceed with a diagnostic right heart catheterization and potential initiation of pulmonary arterial hypertension‐directed therapy in PH‐ILD patients.